Neurocrine Biosciences has initiated a first-in-human Phase 1 study of NBIP-1968, a once-weekly experimental obesity treatment designed to activate the GLP-1, GIP and glucagon receptors through a single molecule.
The August 7, 2026 development marks Neurocrine Biosciences’ entry into clinical testing with an incretin-based obesity candidate. The study will initially examine single ascending doses in adults across several body mass index categories, including people who are overweight or have obesity.
The company is starting with safety and tolerability rather than attempting to prove competitive weight loss. Investigators must determine how the molecule behaves in humans, how long it remains in the body and whether its glucagon activity can be balanced against gastrointestinal, cardiovascular and glucose-related effects.
NBIP-1968 is entering a field whose standards have already moved far beyond modest weight reduction. Eli Lilly and Company’s retatrutide, which activates the same three receptors, produced average weight loss of 28.3% at 80 weeks with its highest dose in the pivotal TRIUMPH-1 trial. The company plans to seek United States approval for retatrutide in the first quarter of 2027.
That result gives Neurocrine Biosciences a powerful scientific validation for the triple-agonist concept, but it also creates a formidable comparison. NBIP-1968 is beginning Phase 1 while retatrutide has completed multiple Phase 3 studies. A similar mechanism will therefore be insufficient by itself. Neurocrine Biosciences will eventually need differentiation through tolerability, body composition, dose convenience, metabolic effects or the planned combination of NBIP-1968 with its separate muscle-focused candidate NBIP-2118.
What has Neurocrine disclosed about the NBIP-1968 Phase 1 study?
The Phase 1 study will initially administer single ascending doses of NBIP-1968 to adult participants across a range of body mass index categories. The inclusion of people who are overweight or have obesity should allow investigators to examine pharmacology in bodies that more closely resemble the intended treatment population.
Single-ascending-dose studies generally begin with a low dose before progressing to higher exposure levels after reviewing safety information from the preceding group. This structure is intended to identify adverse reactions, characterize pharmacokinetics and establish a rational range for subsequent multiple-dose testing.
Neurocrine Biosciences has not publicly provided the planned enrolment, individual dose levels, number of cohorts, study locations or expected date for initial NBIP-1968 results. The announcement also did not describe whether placebo will be used during the initial portion or whether a multiple-ascending-dose stage is already incorporated into the protocol.
Those omissions limit what can be inferred from the trial initiation. Starting a Phase 1 study confirms that manufacturing, nonclinical and regulatory preparations have progressed sufficiently for human exposure. It does not demonstrate that the molecule has produced weight loss in people or that the selected receptor balance will be clinically useful.
Early body-weight changes could appear during the trial, particularly at higher doses. Any such signals would be exploratory because a single-dose study is not designed to establish durable obesity treatment efficacy.
How is NBIP-1968 supposed to produce weight loss?
NBIP-1968 is a long-acting peptide engineered to activate three hormone receptors involved in appetite, glucose regulation and energy balance.
GLP-1 receptor activation can increase glucose-dependent insulin secretion, suppress glucagon after meals, slow gastric emptying and reduce appetite. This mechanism forms the foundation of semaglutide, marketed for obesity as Wegovy, and contributes to the activity of several newer medicines.
GIP receptor activation also enhances glucose-dependent insulin secretion. Its role in weight regulation is more complicated, but clinical results with the dual GIP and GLP-1 receptor agonist tirzepatide have established that the combination can produce greater average weight reduction than earlier GLP-1 monotherapy in relevant comparative settings.
Glucagon has a less immediately intuitive role in an obesity medicine because it can stimulate the liver to release glucose. It may also increase energy expenditure, affect fat metabolism and contribute to appetite regulation. Pairing glucagon activity with GLP-1 and GIP signalling is intended to capture these metabolic effects while the incretin components support glucose control.
The challenge is not simply activating all three receptors as strongly as possible. Each component has different physiological effects, and the proportion of activity across the receptors can materially influence efficacy and tolerability.
Neurocrine Biosciences said NBIP-1968 was designed with balanced glucagon receptor activity. The company has not disclosed detailed receptor-potency ratios, human exposure targets or comparative preclinical results showing how its balance differs from retatrutide.
“Balanced” should therefore be viewed as a design objective, not a clinically demonstrated advantage.
Why is glucagon the most consequential part of the triple-agonist design?
Adding glucagon distinguishes a triple agonist from approved single and dual incretin treatments. It may help increase energy expenditure and enhance fat reduction, potentially allowing a molecule to act on both sides of the weight equation by reducing energy intake and changing energy use.
The same activity can create complications. Excessive glucagon signalling may raise blood glucose, counteracting part of the glycaemic benefit expected from GLP-1 and GIP activation. It can also influence heart rate, amino-acid metabolism, liver function and other physiological systems.
The pharmacological task resembles tuning three instruments that do not naturally remain at the same volume. Too little glucagon activity may make NBIP-1968 behave like another dual incretin. Too much could weaken glucose control or introduce safety and tolerability problems that outweigh incremental weight loss.
The Phase 1 programme should help Neurocrine Biosciences determine whether increasing doses generate the intended metabolic profile. Investigators will be looking for a dose at which exposure appears sufficient for once-weekly treatment without producing unacceptable nausea, vomiting, diarrhoea, appetite suppression, heart-rate changes or glucose instability.
This balancing exercise becomes particularly important because obesity medicines are intended for prolonged use. A side effect that appears manageable after one dose can become treatment-limiting when repeated every week for months or years.
What does Eli Lilly’s retatrutide reveal about the potential of NBIP-1968?
Retatrutide offers the strongest human validation yet for targeting GLP-1, GIP and glucagon receptors together.
In TRIUMPH-1, adults with obesity or overweight and a weight-related condition, but without diabetes, lost an average of 19% of body weight with the four-milligram dose, 25.9% with nine milligrams and 28.3% with 12 milligrams at 80 weeks. Participants receiving placebo lost 2.2%.
A prespecified extension involving participants who began with a body mass index of at least 35 showed average weight loss of 30.3% at 104 weeks among those assigned to the highest-dose group and able to continue treatment under the extension criteria.
Retatrutide has also produced positive Phase 3 results in adults with obesity and type 2 diabetes and in people with severe obesity and established cardiovascular disease. Average weight loss reached 20.8% in the highest-dose diabetes group and 22.6% in the highest-dose cardiovascular-disease group at 80 weeks.
These figures cannot be transferred to NBIP-1968. Molecules targeting the same receptors can differ substantially in potency, receptor balance, half-life, dose escalation, tissue exposure and adverse-event profile.
Retatrutide’s results nevertheless establish a demanding development benchmark. By the time NBIP-1968 reaches proof-of-concept testing, physicians may be comparing it not only with Wegovy and Zepbound but with an approved triple agonist supported by a large Phase 3 programme.
Neurocrine Biosciences may consequently need more than a competitive percentage of weight loss. A lower discontinuation rate, easier titration, better preservation of muscle, improved liver or cardiovascular markers, or more convenient administration could become equally important.
Why will tolerability matter as much as weight loss?
The highest retatrutide dose produced exceptional average weight reduction in TRIUMPH-1, but gastrointestinal adverse events increased with dose.
Nausea was reported in 42.4% of participants receiving 12 milligrams, compared with 14.8% in the placebo group. Vomiting occurred in 25.3%, diarrhoea in 32% and constipation in 26.1% of participants at that dose.
Treatment discontinuation because of adverse events occurred in 11.3% of the 12-milligram retatrutide group, compared with 4.9% of participants receiving placebo. The four-milligram dose produced less weight loss but had an adverse-event discontinuation rate of 4.1%.
Those results demonstrate why the most potent dose is not automatically the best commercial dose. A medicine that produces extremely high average weight loss may still leave room for another treatment that is easier to start, easier to continue or better suited to patients who cannot tolerate aggressive escalation.
Neurocrine Biosciences said current obesity treatments can face challenges involving gastrointestinal tolerability, titration and muscle loss. Phase 1 must show that NBIP-1968 can move through therapeutically relevant exposure levels without reproducing those limitations at an unacceptable intensity.
Later studies will need to report not only the percentage of participants experiencing nausea or diarrhoea but their severity, duration, relationship to dose increases and effect on treatment continuation. Slow titration may improve tolerability, but it can also delay the full therapeutic effect and complicate fixed-dose combination development.
Why is Neurocrine planning to combine NBIP-1968 with NBIP-2118?
Neurocrine Biosciences intends to develop NBIP-1968 for use in a fixed-dose combination with NBIP-2118, a separate once-weekly peptide that activates the corticotropin-releasing factor type 2 receptor.
NBIP-2118 entered its own Phase 1 study in May 2026. Neurocrine Biosciences said preclinical models showed that the candidate reduced weight primarily through fat loss while preserving or increasing lean mass, including skeletal muscle.
That remains a preclinical claim. The first NBIP-2118 study is evaluating single ascending doses in healthy-weight adults and people who are overweight or have obesity, with initial data expected in 2027.
The proposed combination reflects a broader change in obesity-drug development. Once medicines can routinely produce substantial total weight loss, attention shifts toward the composition and quality of that loss.
Some lean tissue is typically lost during significant weight reduction, whether achieved through diet, surgery or medication. The clinical importance varies according to age, starting muscle mass, physical activity, nutrition and underlying illness. Older adults and people with limited mobility may be particularly vulnerable to weakness if muscle loss becomes excessive.
Neurocrine Biosciences wants NBIP-1968 to provide strong incretin-based weight reduction while NBIP-2118 helps direct more of that reduction toward fat. If the concept works, the combination could address a problem that becomes more visible as increasingly powerful obesity medicines enter clinical use.
Both components must first succeed independently. A fixed-dose combination cannot rescue a triple agonist with poor tolerability, and preclinical muscle preservation does not guarantee that NBIP-2118 will produce the same effect in people.
How difficult will fixed-dose combination development be?
Combining two experimental peptides introduces scientific and regulatory complexity beyond developing either medicine alone.
Neurocrine Biosciences must determine the effective dose of NBIP-1968, the effective dose of NBIP-2118 and the appropriate ratio between them. If patients require different titration speeds for the two components, a fixed-dose presentation could reduce prescribing flexibility.
The company will also need to establish whether the medicines affect each other’s absorption, distribution, metabolism or tolerability. Overlapping effects on appetite, energy balance, heart rate or gastrointestinal function could strengthen efficacy or create unexpected adverse reactions.
Regulators generally need evidence showing the contribution of each component in a combination medicine. Later trials may therefore require groups receiving NBIP-1968 alone, NBIP-2118 alone, the combination and placebo or an active comparator.
Manufacturing creates another layer. Both peptides must remain stable, retain consistent potency and be compatible with the intended delivery system. Neurocrine Biosciences has not disclosed whether the eventual fixed-dose product would place both molecules in a single injection or use another administration arrangement.
The combination strategy has considerable differentiation potential, but it also extends the development path. Retatrutide is approaching regulatory submission as a standalone triple agonist while Neurocrine Biosciences is beginning human testing of two separate components that must eventually be integrated.
What evidence would show that NBIP-2118 is preserving muscle?
Body weight alone cannot answer whether a treatment preferentially reduces fat.
Later trials would need body-composition measurements capable of separating fat mass from lean mass. Dual-energy X-ray absorptiometry is frequently used for this purpose, while magnetic resonance imaging can provide more detailed information about muscle and fat distribution.
Preserving measured lean mass is not necessarily equivalent to preserving muscle function. Hydration, organs and connective tissues contribute to lean-mass measurements, making functional assessments valuable.
Hand-grip strength, walking speed, chair-rise performance and other physical-function measures could help determine whether changes in body composition translate into a meaningful patient benefit. Nutrition and resistance exercise would also need to be considered because both can influence muscle during weight loss.
The strongest evidence would show that adding NBIP-2118 to NBIP-1968 preserves more skeletal muscle or physical function than NBIP-1968 alone while maintaining clinically meaningful fat loss and acceptable safety.
That is a higher evidentiary bar than showing weight reduction in an animal model. Neurocrine Biosciences has identified an important unmet need, but the company must still prove that CRF2 receptor activation addresses it in humans.
Why is Neurocrine Biosciences moving beyond its traditional therapeutic areas?
Neurocrine Biosciences is best known for medicines targeting neurological, psychiatric and endocrine disorders. Its commercial portfolio includes treatments for tardive dyskinesia, Huntington’s disease chorea, congenital adrenal hyperplasia and hyperphagia associated with Prader-Willi syndrome.
Obesity represents a significant expansion, but it is not completely disconnected from the company’s scientific background. Appetite, reward, hormonal signalling and energy balance involve complex communication between the brain and peripheral organs.
The NBIP-2118 programme also builds on Neurocrine Biosciences’ experience with corticotropin-releasing factor biology, creating a bridge between its endocrine research and metabolic development.
Commercial opportunity is only part of the rationale. The obesity market increasingly rewards companies that can combine central nervous system biology, endocrinology, peptide engineering and long-term chronic-disease development.
The strategic risk is that Neurocrine Biosciences is entering against companies with far larger metabolic franchises, established obesity sales forces, global peptide manufacturing capacity and extensive payer relationships. Eli Lilly and Company and Novo Nordisk are not waiting politely at the finish line.
Neurocrine Biosciences will need a clear clinical identity for its portfolio. The muscle-preservation strategy provides one, but only if clinical data support it.
How crowded will the obesity market be when NBIP-1968 reaches later trials?
The competitive environment is evolving faster than a conventional drug-development timeline.
Wegovy established the modern market for highly effective GLP-1 obesity treatment. Zepbound raised the efficacy standard through combined GIP and GLP-1 receptor activation. Oral medicines such as Foundayo are expanding the range of administration choices, while retatrutide could establish triple-receptor treatment before NBIP-1968 leaves early development.
Other developers are pursuing GLP-1 and glucagon dual agonists, amylin combinations, long-acting injections, oral peptides, small molecules and treatments designed to preserve muscle. Competition is shifting from a simple question of which medicine produces the greatest weight loss toward matching different products to different patients.
Some people may prioritize maximum weight reduction. Others may value fewer gastrointestinal effects, oral dosing, longer intervals between injections, muscle preservation, glucose control or benefits in conditions such as sleep apnea, fatty liver disease and cardiovascular disease.
NBIP-1968 may still find a meaningful position if its receptor balance produces a distinctive clinical profile. Its late entry means that similarity to existing products will carry less value than measurable differentiation.
A programme that eventually combines powerful fat reduction with convincing muscle preservation could attract attention even in a crowded market. A molecule offering another weekly injection with broadly comparable efficacy and tolerability would face a much tougher commercial path.
What safety signals must the first study examine?
The initial safety assessment should extend beyond familiar gastrointestinal effects.
Investigators will monitor nausea, vomiting, diarrhoea, constipation, abdominal discomfort and appetite suppression. These events may indicate biological activity, but severity and persistence will determine whether repeated administration is practical.
Heart rate and blood pressure will be important because glucagon-containing agonists can influence cardiovascular physiology. Electrocardiograms and laboratory monitoring can help identify rhythm changes or other early concerns.
Glucose must be followed closely. GLP-1 and GIP activity may improve glucose control, while glucagon can increase hepatic glucose output. The combined effect will depend on dose, receptor balance and participant characteristics.
Liver enzymes, lipid markers and ketone-related metabolic changes may also provide useful information. Because NBIP-1968 is a peptide, investigators will assess injection-site reactions and the development of antibodies against the medicine.
Pharmacokinetic data must support the proposed once-weekly schedule. If exposure declines too rapidly, the medicine may not provide consistent receptor activity. If it accumulates more than expected, repeated dosing could amplify adverse effects.
The study must additionally show whether people with obesity process the medicine differently from participants at lower body mass index levels. That is one reason for including several BMI categories during early development.
What results would make NBIP-1968 a credible challenger?
The first meaningful milestone will be a clean dose-escalation profile that allows Neurocrine Biosciences to reach exposures expected to influence all three receptors.
Evidence of a half-life compatible with once-weekly dosing would support the intended treatment schedule. Early changes in appetite, glucose, insulin, glucagon, lipids or body weight could provide pharmacodynamic confirmation, although none would establish efficacy after a single dose.
A subsequent multiple-dose study must show that tolerability remains manageable as exposure accumulates. Dose escalation, maximum tolerated dose and the proportion of participants able to remain on treatment will help determine whether NBIP-1968 has a practical development range.
Proof-of-concept testing will then require sustained weight loss, a favourable proportion of fat reduction and improvements in relevant metabolic markers. Direct body-composition measurements will become particularly important before the programme advances toward combination testing with NBIP-2118.
Neurocrine Biosciences must eventually decide whether NBIP-1968 can compete independently or whether its strongest value exists only as one half of the planned fixed-dose combination. That decision will affect trial design, manufacturing investment and development speed.
Can Neurocrine carve out space in the next obesity-drug generation?
The start of the NBIP-1968 Phase 1 study gives Neurocrine Biosciences a credible entry into the triple-agonist obesity field, but it begins the clinical test rather than settling it.
The biological concept is no longer speculative. Eli Lilly and Company has shown that coordinated GLP-1, GIP and glucagon receptor activation can generate weight reduction approaching levels historically associated with bariatric surgery in some trial populations.
That validation is both helpful and unforgiving. Neurocrine Biosciences does not need to prove that triple agonism can work in principle. It must demonstrate why NBIP-1968 deserves development in a market likely to contain a much more advanced medicine with the same three named targets.
The planned NBIP-2118 combination offers the clearest possible answer. Greater fat loss with better muscle preservation would address a clinically relevant limitation of high-intensity weight reduction and create differentiation beyond a headline percentage on the scale.
Several layers of evidence remain missing. Neither candidate has reported human data, the optimal doses are unknown, the fixed combination has not entered clinical testing and the company has not disclosed when NBIP-1968 results will become available.
Phase 1 will first determine whether Neurocrine Biosciences has built a controllable triple agonist. If safety, pharmacokinetics and receptor balance support repeated dosing, the programme can begin answering the larger question of whether another weekly obesity injection can offer something the emerging market does not already have.
NBIP-1968 is arriving late enough to face an intimidating benchmark, but early enough for the obesity market’s final shape to remain unsettled. Its opportunity lies less in copying the success of retatrutide than in showing that major weight loss does not have to come with the same tolerability, titration or muscle-composition trade-offs.
